The project “New technologies for target discovery in neuropsychiatric disorders” was selected for funding in the Technological Convergence Related to Enabling Technologies call of the Norwegian Research Council. The project will be led by Jan Haavik with CBU group leader Tom Michoel as a partner. The group of Tom Michoel will be responsible for integrating large-scale pharmacogenomics data for target gene selection in a drug discovery pipeline.